Automating and scaling a comprehensive genomic profiling workflow can be a tedious and challenging process that requires lots of time and resources. However, an intelligent clinical decision support platform and on-demand expert support services can make all the difference. 

In this webinar, learn about QIAGEN Clinical Insight (QCI) Interpret for Oncology, a clinical decision support platform that has been trusted to analyze and interpret more than 3 million patient molecular profiles worldwide. Unlike other commercial solutions, QCI Interpret for Oncology is powered by augmented molecular intelligence and offers in-software access to a team of variant scientists to assist you with rare or novel variant research, curation, and interpretation. The platform connects to the QIAGEN Knowledge Base—the highest quality genomic knowledge base in the industry—and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines. To help you further scale and reduce hands-on time, QCI Interpret for Oncology provides over 410,000 variant interpretation summaries that have all been reviewed by oncologists. This enables you to quickly build custom reports for your oncologists and their patients with the latest diagnostic and prognostic information, as well as biomarker-directed therapy and clinical trial recommendations.

By attending this webinar, you will:

  • Receive a step-by-step guide of how to go from VCF to final report using QCI Interpret for Oncology 
  • Learn about the platform’s automated variant classification process
  • Learn how QIAGEN uses augmented molecular intelligence to enhance our expert curation process
  • See first-hand how to build a custom report with an opportunity to submit your own VCF file for a sample report
About the speaker
Umadevi Thirumurthi, PhD, Associate Director of Global Product Management, Somatic Oncology
QIAGEN Digital Insights
Umadevi Thirumurthi, Ph.D., is the Associate Director of Global Product Management, Somatic Oncology at QIAGEN Digital Insights. Prior to joining QIAGEN in Nov 2022, Dr. Thirumurthi was at Sema4 (now GeneDx), where she played a lead role in the development of their in-house Cancer Knowledgebase to support clinical reporting of the Sema4 Solid Tumor and Whole Exome/Transcriptome tests. During her tenure at Sema4, besides supporting the clinical oncology workflow, she was also instrumental in building tools and software solutions in collaboration with bioinformatics and software units and closely working with the business development, marketing, and product units within Sema4 to assist in launching oncology products into the market. Other past work included identifying novel pathways to target cancer stem cells at Merrimack Pharmaceuticals.Dr. Thirumurthi has a Ph.D. in Cancer Biology from UTHSC MD Anderson Cancer Center and a Master’s in Molecular Biotechnology from Wayne State University.
Date of recording:Thursday, 22 June, 2023
Duration:60 minutes
Categories
Webinar
Human Genetics
Bioinformatics - Clinical Interpretation and Reporting
Bioinformatics
Informatics & Data